论文部分内容阅读
目的：探讨双次自体造血干细胞移植对恶性血液病的临床疗效。方法：回顾性分析我院 １９９５年～１９９９年间１２例双次自体造血干细胞移植的资料，并与同期１７例单次自体移植效果比较。结果：双次移植１２例患者移植后持续缓解６～６８个月，中位数２７个月，其中８例（６６．７％）至今无病生存，１例于第二次移植后６个月出现复发，３例死于移植相关性疾病。单次自体移植１７例患者移植后持续缓解１～３６个月，中位数１２个月，其中６例（３．３％）至今无病生存，８例肿瘤复发，３例死于移植相关性疾病。结论：双次自体造血干细胞移植治疗恶性血液病的疗效较好，其移植后１８个月生存率有优于单次自体造血于细胞移植的趋势。
Objective: To investigate the clinical efficacy of double hematopoietic stem cell transplantation for hematological malignancies. Methods: The data of 12 cases of double autologous hematopoietic stem cell transplantation in our hospital from 1995 to 1999 were retrospectively analyzed and compared with the results of 17 single autografts in the same period. RESULTS: Twelve patients underwent double-transplantation and sustained relief for 6 to 68 months after transplantation, with a median of 27 months. Of these patients, 8 (66.7%) had survived without disease, and 1 patient had 6 months after the second transplantation. Recurrence occurred and 3 patients died of transplant-related diseases. In a single autologous transplantation, 17 patients had sustained remission after transplantation for 1 to 36 months with a median of 12 months. Among them, 6 (3.3%) had survived without disease, 8 had tumor recurrence, and 3 died of transplant-related disease. disease. Conclusion: The effect of double autologous hematopoietic stem cell transplantation for the treatment of hematological malignancies is good. The 18-month survival rate after transplantation is better than the single autologous hematopoietic and cell transplantation.